Compounds > n-(4-carboxyphenyl)retinamide
Page last updated: 2024-12-11

n-(4-carboxyphenyl)retinamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6505394
MeSH IDM0133149

Synonyms (20)

Synonym
ccris 5521
4-(hydroxycarbophenyl)retinamide
4-carboxyphenylretinamide
n-(p-carboxyphenyl)retinamide
sri 7167-67
basf 35681
retinamide, n-(4-carboxyphenyl)-
n-(4-carboxyphenyl)retinamide
74193-17-2
unii-qgj09ho5s0
qgj09ho5s0 ,
4-[[(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoyl]amino]benzoic acid
DTXSID40225179
n-4-carboxyphenylretinamide
rii-retinamide
retinamide (rii)
benzoic acid, 4-((15-oxoretin-15-yl)amino)-
retinamidic acid
basf-35681
n-4 (car-boxyphenyl) retinamide

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic characteristics of RII were studied by HPLC in thirteen cancer patients after oral administration."( [Pharmacokinetic study of 4-(hydroxycarbophenyl) retinamide (RII) in cancer patients].
Gu, QM, 1989)		0.28

Dosage Studied

ExcerptRelevanceReference
"Our studies show that the growth of transplantable chondrosarcoma in rats is inhibited significantly by N-4-(hydroxycarbophenyl) retinamide (RII) at a dosage of 50 mg/kg."( [Pharmacological studies of N-4-(hydroxycarbophenyl) retinamide].
Han, R, 1991)		0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (55.56)18.7374
1990's4 (44.44)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.02 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
dimethyl sulfoxide
Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.		1.9610sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
nitroblue tetrazolium
Nitroblue Tetrazolium: Colorless to yellow dye that is reducible to blue or black formazan crystals by certain cells; formerly used to distinguish between nonbacterial and bacterial diseases, the latter causing neutrophils to reduce the dye; used to confirm diagnosis of chronic granulomatous disease.		1.9610organic cation
n-nitrososarcosine ethyl ester
[no description available]		1.9710
tretinoin
Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.		3.5890retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
4-(carboethoxyphenyl)retinamide
viaminate: structure in first source		2.3720
ConditionIndicatedRelationship StrengthStudiesTrials
Carcinoma, Ehrlich Tumor
A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.		02.3720
Acute Myelogenous Leukemia
[description not available]		01.9610
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		01.9610
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		01.9810
Cancer of Stomach
[description not available]		02.3820
Stomach Neoplasms
Tumors or cancer of the STOMACH.		02.3820
Carcinoma, Epidermoid
[description not available]		01.9810
Cancer of Nasopharynx
[description not available]		01.9810
Invasiveness, Neoplasm
[description not available]		01.9810
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		01.9810
Nasopharyngeal Neoplasms
Tumors or cancer of the NASOPHARYNX.		01.9810
Acute Promyelocytic Leukemia
[description not available]		01.9710
Chondrosarcoma
A slowly growing malignant neoplasm derived from cartilage cells, occurring most frequently in pelvic bones or near the ends of long bones, in middle-aged and old people. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS. (Stedman, 25th ed)		01.9710
Leukemia, Promyelocytic, Acute
An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.		01.9710
Cancer of Esophagus
[description not available]		02.3720
Esophageal Neoplasms
Tumors or cancer of the ESOPHAGUS.		02.3720
Bladder Cancer
[description not available]		01.9710
Cancer of Lung
[description not available]		01.9710
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.		01.9710
Lung Neoplasms
Tumors or cancer of the LUNG.		01.9710